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Maternal circulating Vitamin D3  
levels during pregnancy and 
behaviour across childhood
Mónica López-Vicente1,2,3,4, Jordi Sunyer1,2,3,4, Nerea Lertxundi5,6, Llúcia González7,8, 
cristina Rodríguez-Dehli9, Mercedes espada Sáenz-torre10, Martine Vrijheid1,2,3, 
Adonina tardón  2,11, Sabrina Llop2,8, Maties torrent12, Jesús ibarluzea2,5,6,13 & 
Mònica Guxens1,2,3,14
Vitamin D deficiency during critical periods of development could lead to persistent brain alterations. 
We aimed to assess the association between maternal vitamin D3, the major circulatory form of vitamin 
D, at pregnancy and neurodevelopmental outcomes during childhood, namely: behavioural problems, 
Attention Deficit and Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD) symptoms, 
and social competence. This study included 2,107 mother-child pairs of a Spanish population-based 
birth cohort. Maternal plasma vitamin D3 was measured in pregnancy. The outcomes were measured 
through questionnaires at 5, 8, 14, and 18 years old. We ran multivariate regression models adjusted 
for potential confounding variables. We found that per each 10 ng/mL increment of maternal vitamin 
D3, children obtained higher social competence scores (coefficient = 0.77; 95% CI = 0.19, 1.35) at 5 
years old. However, we observed null associations between maternal vitamin D3 and total behavioural 
problems and ADHD and ASD symptoms in children from 5 to 18 years old. Further studies carried out in 
countries where the population is exposed to lower vitamin D levels are needed.
Vitamin D is a hormone that is involved in the formation of bone and in the regulation of several functions 
throughout the body, including the central nervous system function1. There are two forms of vitamin D, depend-
ing on the source: D2, of plant origin, and D3, of animal origin1. The majority of circulating vitamin D is in D3 
form2,3, which is mainly produced photochemically in the epidermis by action of ultraviolet light1,4 and a small 
proportion comes from diet, principally from fish, eggs, and milk5. Vitamin D from the skin and diet is metab-
olized in the liver to 25-hydroxy-vitamin D (25[OH]D), the circulating form, which is one of the most stable 
vitamin D biomarkers, and in the kidney to 1,25-(OH)D, the active form1. During gestation, the foetus is entirely 
dependent on the maternal supply of 25(OH)D6.
Vitamin D modulates the central nervous system function mainly through its nuclear hormone receptor, 
the vitamin D receptor, which is expressed in neuronal and glial cells in almost all regions of the central nerv-
ous system7. It controls neuronal differentiation and maturation, regulates the genetic expression of neurotrans-
mitters, and it has neuroprotective properties and antioxidant effects1. Vitamin D deficiency is a public health 
problem worldwide, particularly for darker skinned individuals living further away from the equator8. If this 
deficiency occurs during critical periods of development, it could lead to changes that persist through adult-
hood, and increases the risk of different psychiatric and neurological disorders, such as schizophrenia, multiple 
sclerosis, dementia, cognitive decline, Parkinson disease, and depression9. Some studies have investigated the 
association between vitamin D concentrations during pregnancy and neurodevelopmental outcomes, such as 
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behavioural problems and social competence, in the offspring. Three independent studies observed no associ-
ations between maternal 25(OH)D measured in blood at 18, 26, and 33 weeks of pregnancy, respectively, and 
behavioural problems during childhood9–11. However, a recent study observed that higher maternal 25(OH)D 
concentration (>20.4 ng/mL) at week 13 of pregnancy was related to a lower number of behavioural problems 
and attention deficit and hyperactivity disorder (ADHD) symptoms at 4 years old12. Two other studies, one of 
them developed in our cohort, the Spanish population-based birth cohort INMA (INfancia y Medio Ambiente 
[Childhood and Environment]), also reported negative associations between prenatal 25(OH)D3 and ADHD 
symptoms at preschool age13,14. The evidence for an association between prenatal levels of 25(OH)D and autism 
spectrum disorder (ASD) symptoms is inconsistent, while some studies found negative relationships6,15–19, others 
obtained null results20,21. Nevertheless, a recently conducted meta-analysis showed negative associations between 
prenatal 25(OH)D3 and both ADHD and ASD symptoms22. Moreover, low concentrations of 25(OH)D during 
pregnancy have shown to be associated with delayed social development in toddlers23,24. Unlike the other men-
tioned outcomes, this domain is not considered a clinical phenotype, however, it encompasses several aspects of 
adaptive behavioural development with long-term consequences, such as unemployment, mental health prob-
lems, marital difficulties, delinquency, or violence25.
Further research on the association between prenatal 25(OH)D concentration and behaviour during child-
hood is needed. This study aims to assess the association between maternal circulating vitamin D3 (25[OH]D3) in 
pregnancy, when key neuronal maturation processes take place in the foetus, and behavioural problems, ADHD 
and ASD symptoms, and social competence from 5 to 18 years old in the INMA cohort, which is based in differ-
ent regions of Spain.
Results
The characteristics of the entire sample and by the three clinically relevant categories of maternal 25(OH)D3 con-
centration in plasma during pregnancy are described in Supplementary Table S1. The study population included 
50.8% male children and 56.4% firstborn. Ninety-four percent of the mothers were born in Spain, and maternal 
mean age was 30.7 (4.2) years old. Twenty-five percent of the mothers were overweight or obese before preg-
nancy, 25.8% had a low education level (primary or less) and 34% had high education level (university). Half of 
the mothers had a manual occupation, 17% of the mothers were smokers during the first trimester of pregnancy, 
and 29% reported that their partners smoked at home. Eighteen percent of the women (n = 372) had deficient 
concentrations of 25(OH)D3 (<20 ng/mL) during pregnancy. The highest concentrations of circulating 25(OH)
D3 were observed in Valencia (mean [SD] 32.8 [10.8] ng/mL), and the lowest, in Asturias (mean [SD] 28 [10.2] 
ng/mL). Higher concentrations of 25(OH)D3 were detected in women from high education level and from man-
agers/technicians occupation category, and those born in Europe, including Spain, as opposed to those women 
born in Latin America. Lower 25(OH)D3 concentrations were measured in younger women and in women with 
pre-pregnancy overweight or obesity, primiparous, active smokers and with partners smoking at home during 
pregnancy.
Behavioural problems, ADHD symptoms, ASD symptoms, and social competence were assessed using differ-
ent instruments and at different children’s ages in each of the regions (Supplementary Table S2). Supplementary 
Table S3 shows the distribution of the outcomes included in this study according to the categories of maternal 
25(OH)D3. Children prenatally exposed to deficient concentrations of 25(OH)D3 (<20 ng/mL) showed more 
ASD symptoms, more total behavioural problems, and less social competence at 5 years old, as compared to their 
peers exposed to higher concentrations. This group of children with low concentrations of 25(OH)D3 during 
gestation had more ADHD symptoms at 8 years old and more total behavioural problems at 8 and at 14 years old. 
However, this pattern was not observed at 18 years old.
Table 1 shows the associations between prenatal 25(OH)D3 concentrations and the neurodevelopmental out-
comes. Regarding the outcomes measured at 5 years old, the regression models indicated that sufficient 25(OH)D3 
concentrations during pregnancy (≥30 ng/ml) were associated with lower ASD symptoms (coefficient = −0.54; 
95% CI = −1.01, −0.07) compared to deficient 25(OH)D3 concentrations, and that insufficient concentra-
tions (20–29.9 ng/ml) were associated with lower total behavioural problems measured with the Strengths and 
Difficulties Questionnaire (SDQ) (coefficient = −1.65; 95% CI = −3.27, −0.03) compared to deficient 25(OH)D3 
concentrations, although these associations were no longer present in the fully adjusted models. The association 
with social competence remained after adjusting for potential confounding variables, using the exposure varia-
ble as continuous and categorical forms. Per each 10 ng/mL increment of maternal 25(OH)D3 concentration in 
pregnancy, children obtained 0.77 (95% CI = 0.19, 1.35) points more of social competence. Similarly, the score 
was 2.14 (95% CI = 0.47, 3.82) points higher in children with sufficient prenatal concentrations of 25(OH)D3 
versus children with deficient concentrations. A positive association was also detected in the insufficient cate-
gory (coefficient = 2.09; 95% CI = 0.33, 3.84), which was not observed in the fully adjusted model. The associ-
ations observed between maternal 25(OH)D3 in pregnancy, treated as continuous and categorical variable, and 
total behavioural problems and ADHD symptoms in the offspring at 8, 14, and 18 years old were almost null. 
We observed that insufficient 25(OH)D3 concentrations (20–29.9 ng/mL) category was associated with lower 
total behavioural problems score measured with the Child Behaviour Checklist (CBCL) (Incidence Rate Ratio 
[IRR] = 0.86; 95% CI = 0.76, 0.97), compared to de deficiency category (<20 ng/ml), but this association was no 
longer found after adjusting for potential confounding variables.
As sensitivity analysis, no associations were detected between child 25(OH)D3 concentrations and the out-
comes in the subsample of children with available child 25(OH)D3 concentrations. The association between pre-
natal 25(OH)D3 and child social competence remained when we restricted the analysis to the sample of children 
with both prenatal and child 25(OH)D3 data available (Supplementary Table S4).
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Discussion
We explored the associations between maternal 25(OH)D3 concentration during pregnancy and a wide range of 
behavioural problems, including ADHD and ASD symptoms, and social competence in children at different ages 
using data from a population-based birth cohort located in five regions across Spain. Our findings indicated a 
positive association between prenatal 25(OH)D3 concentrations and social competence at 5 years of age. However, 
we observed null associations of prenatal 25(OH)D3 concentration with total behavioural problems, ADHD and 
Domains Instruments Regions Levels (n) Unadjusted Minimally adjustedc Fully adjustedd
ASD symptoms CAST-5ya (coef, 95% CI) V, S, A, G
Continuous (per 
10 ng/mL) (1510) −0.14 (−0.29, 0.01) −0.10 (−0.25, 0.04) −0.02 (−0.17, 0.12)
<20 ng/mL (259) Reference
20–29.9 ng/mL (534) −0.23 (−0.72, 0.26) −0.25 (−0.72, 0.22) −0.14 (−0.61, 0.32)
≥30 ng/mL (717) −0.54 (−1.01, −0.07) −0.48 (−0.94, −0.02) −0.26 (−0.71, 0.19)
Social competence CPSCS-5ya (coef, 95% CI) V, S, A, G, M
Continuous (per 
10 ng/mL) (1481) 1.22 (0.63, 1.81) 0.97 (0.39, 1.55) 0.77 (0.19, 1.35)
<20 ng/mL (279) Reference
20–29.9 ng/mL (538) 2.09 (0.33, 3.84) 1.97 (0.24, 3.69) 1.42 (−0.29, 3.12)
≥30 ng/mL (664) 3.42 (1.72, 5.12) 2.84 (1.16, 4.52) 2.14 (0.47, 3.82)
Total behavioural 
problems SDQ-5y
a (coef, 95% CI) G
Continuous (per 
10 ng/mL) (263) −0.24 (−0.78, 0.30) — −0.01 (−0.53, 0.51)
<20 ng/mL (39) Reference
20–29.9 ng/mL (124) −1.65 (−3.27, −0.03) — −0.90 (−2.44, 0.63)
≥30 ng/mL (100) −1.02 (−2.70, 0.65) — −0.13 (−1.75, 1.48)
Total behavioural 
problems SDQ-8y
a (coef, 95% CI) V, S, A, G
Continuous (per 
10 ng/mL) (1622) −0.08 (−0.32, 0.15) −0.13 (−0.37, 0.10) 0.00 (−0.23, 0.24)
<20 ng/mL (288) Reference
20–29.9 ng/mL (576) −0.44 (−1.16, 0.29) −0.51 (−1.24, 0.22) −0.31 (−1.02, 0.41)
≥30 ng/mL (758) −0.44 (−1.14, 0.26) −0.60 (−1.30, 0.11) −0.22 (−0.91, 0.48)
Total behavioural 
problems CBCL-8y
b (IRR, 95% CI) V, S, G
Continuous (per 
10 ng/mL) (1206) 0.98 (0.95, 1.02) 0.98 (0.94, 1.02) 1.00 (0.96, 1.04)
<20 ng/mL (202) Reference
20–29.9 ng/mL (415) 0.86 (0.76, 0.97) 0.87 (0.77, 0.99) 0.90 (0.79, 1.01)
≥30 ng/mL (589) 0.92 (0.82, 1.04) 0.91 (0.81, 1.02) 0.96 (0.85, 1.07)
ADHD symptoms CPRS-8yb (IRR, 95% CI) V, S, A, G
Continuous (per 
10 ng/mL) (1622) 1.01 (0.97, 1.05) 1.00 (0.96, 1.04) 1.01 (0.97, 1.06)
<20 ng/mL (288) Reference
20–29.9 ng/mL (576) 0.93 (0.82, 1.06) 0.93 (0.81, 1.05) 0.94 (0.83, 1.07)
≥30 ng/mL (758) 0.96 (0.85, 1.09) 0.94 (0.83, 1.06) 0.98 (0.86, 1.11)
Total behavioural 
problems SDQ-14y
a (coef, 95% CI) M
Continuous (per 
10 ng/mL) (198) −0.46 (−1.13, 0.21) — −0.27 (−0.95, 0.41)
<20 ng/mL (34) Reference
20–29.9 ng/mL (82) −0.81 (−2.59, 0.97) — −0.43 (−2.23, 1.37)
≥30 ng/mL (82) −1.13 (−2.91, 0.66) — −0.64 (−2.45, 1.17)
Total behavioural 
problems SDQ-18y
a (coef, 95% CI) M
Continuous (per 
10 ng/mL) (149) −0.03 (−0.80, 0.73) — 0.09 (−0.69, 0.86)
<20 ng/mL (24) Reference
20–29.9 ng/mL (58) 1.11 (−0.96, 3.18) — 1.48 (−0.61, 3.58)
≥30 ng/mL (67) 0.54 (−1.49, 2.57) — 0.92 (−1.16, 2.99)
ADHD symptoms CPRS-18yb (IRR, 95% CI) M
Continuous (per 
10 ng/mL) (151) 0.96 (0.81, 1.14) — 0.96 (0.80, 1.14)
<20 ng/mL (25) Reference
20–29.9 ng/mL (60) 1.45 (0.93, 2.27) — 1.33 (0.84, 2.10)
≥30 ng/mL (66) 1.22 (0.79, 1.90) — 1.13 (0.72, 1.77)
Table 1. Associations between maternal 25(OH)D3 concentrations in pregnancy and neurodevelopmental 
outcomes. Domains: ADHD = Attention Deficit and Hyperactivity Disorder; ASD = Autism Spectrum 
Disorder. Instruments: CAST = Childhood Autism Spectrum Test; CBCL = Child Behaviour Checklist; 
CPRS = Conners’ Parent Rating Scale-Revised (short form); CPSCS = California Preschool Social Competence 
Scale; SDQ = Strengths and Difficulties Questionnaire. Regions: A = Asturias; G = Gipuzkoa; M = Menorca; 
S = Sabadell; V = Valencia. aLinear regression model; bNegative binomial regression model; cAdjusted for 
region; dAdjusted for region, maternal age, maternal education level, maternal occupation, maternal country of 
birth, maternal smoking during the 1st trimester of pregnancy, partner smoking at home during the 1st trimester 
of pregnancy. Multiple imputation and inverse probability weighting were applied. Bold = p < 0.05.
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ASD symptoms in children from 5 to 18 years old. Sensitivity analyses showed no associations between the con-
centrations of 25(OH)D3 in children and the outcomes.
In our study, we observed a weak negative association between prenatal 25(OH)D3 and ASD symptoms at 5 
years of age that was not significant upon adjustment for potential confounding variables. These results are in line 
with two Californian studies20,21. On the contrary, previous research carried out in Australian15 and Dutch birth 
cohort studies6,19 found stronger associations with this outcome. The Australian study reported an association 
between lower mid-gestation 25(OH)D concentrations and higher scores on the Attention Switching subscale 
of the Autism-Spectrum Quotient15. In the Dutch studies, infants exposed to persistent low 25(OH)D concen-
trations (<7.9 ng/mL) from mid-gestation until birth showed more autism-related traits at 6 years old19, and 
mid-gestational 25(OH)D deficiency (<7.9 ng/mL) was associated with an increased risk of ASD diagnosis at 9 
years old6. The different findings obtained could be explained by the lower levels of 25(OH)D in Dutch pregnant 
women, as compared to the Spanish sample. Other plausible explanations are the different pregnancy periods at 
blood collection and the different instruments used to assess ASD symptoms. The instrument used in the Dutch 
studies, the Social Responsiveness Scale, is particularly focused on measuring the social deficits associated with 
ASD26. This suggests that prenatal vitamin D could be more related to the social dimension of ASD. The previ-
ously reported positive association between prenatal vitamin D and social development in toddlers23,24 together 
with our findings on social competence at age 5 years reinforces this hypothesis. In our study, we obtained a rela-
tively low effect estimates for the association between prenatal vitamin D levels and social competence. However, 
this effect size is in line with other studies assessing other exposures, such as head circumference27, child sali-
vary cortisol levels at 14 months of age28, and maternal urinary phthalate metabolite levels during pregnancy29. 
Furthermore, although it might not be relevant at a clinical level, the observed effect may have an impact at a pop-
ulation level. If the whole population is exposed to low levels of vitamin D, the distribution of social competence 
scores would likely move to the left, and the prevalence of children with low social competence would increase 
substantially. This increase of social competence problems may have a negative impact on the community in 
terms of unemployment, mental health problems or delinquency25.
We observed no associations between the concentrations of 25(OH)D3 in children and the assessed outcomes 
in a subsample, while the association remained between prenatal 25(OH)D3 and social competence in the same 
group. This finding suggests that the levels of 25(OH)D3 influence child social development exclusively during 
the prenatal period. The biological mechanisms by which maternal vitamin D concentration during pregnancy 
affect the brain development in humans are still unclear. However, some animal studies observed that 25(OH)
D3 deficiency during late gestation was associated with brain morphological alterations in the offspring, such as 
larger lateral ventricles, thinner cortex, and higher cell proliferation30, as well as hyperlocomotion at adulthood31. 
Although the most active period of foetal brain growth lies in the third trimester of pregnancy, key development 
processes, such as neuronal migration, start at week 6 of gestation and usually end around 24 weeks, and vitamin 
D is involved in the modulation of neuronal migration, dendritic spine morphology, and neuronal connectivity1. 
Therefore, the association we observed between 25(OH)D3 concentration in pregnancy and child social compe-
tence could be due to alterations in these neuronal processes.
The null associations detected between maternal 25(OH)D3 concentration in pregnancy and total behavioural 
problems in the offspring are consistent with some previous studies9–11. However, Daraki et al.12 found that higher 
25(OH)D levels (>20.4 ng/mL) were related to decreased number of total behavioural problems in 4-year-old 
children12. In this study, carried out in a Greek cohort, almost two-thirds of pregnant women (n = 313) had 
25(OH)D deficiency (<15.7 ng/mL), which seemed to be explained by darker skin pigmentation, poor dietary 
vitamin D intake, veiled clothing reducing sunshine exposure, and increased prevalence of obesity. This high 
prevalence of 25(OH)D deficiency could explain the different results obtained between this study and ours.
Regarding ADHD symptoms, we found that, despite the associations already observed between prenatal 
25(OH)D3 and ADHD at preschool age in our cohort13 and in the Danish14 and the Greek12 cohorts, these asso-
ciations did not remain at 8 and 18 years old. A possible explanation is that prenatal 25(OH)D3 concentrations 
do not have permanent effects on the brain development, but other factors could modulate these effects across 
the childhood and adolescence, exerting much more influence on ADHD symptoms at 8 and 18 years old than 
prenatal 25(OH)D3. Alternative explanations to the inconsistent findings between preschool age and older age 
in our cohort include the different instruments used in both periods and the different person reporting ADHD 
symptoms. At ages 4–5 years, we administered the ADHD Criteria of Diagnostic and Statistical Manual of Mental 
Disorders (ADHD-DSM-IV) form to the teachers, while at 8 and 18 years old the parents filled in the Conners’ 
Parent Rating Scale-Revised (short form) (CPRS-R [S]). It is known that agreement between parents and teachers 
regarding child ADHD symptoms is relatively poor32. However, previous research performed in a Scandinavian 
study using clinical ADHD diagnosis also reported null associations between prenatal 25(OH)D concentrations 
and ADHD at older ages33,34, which supports the hypothesis about the reversibility of the prenatal vitamin D 
deficiency effects on brain development.
This study has some limitations. First, we only used D3 form of vitamin D, however this is the major cir-
culatory form and is commonly used in endocrinology studies3,30,31. Second, a single 25(OH)D3 measurement 
per subject was obtained, so it was not possible to compare different windows of susceptibility to 25(OH)D3 
deficiency during pregnancy. Third, the heterogeneity in the assessment periods between regions complicated 
the interpretation of the results. Due to the small sample size of adolescents in our study, results on long-term 
associations between prenatal 25(OH)D3 concentrations and behavioural problems at 14 and 18 years old should 
be taken with caution. Moreover, given the prospective nature of the study, we had some loss of participants 
across follow ups. This limitation was minimized by applying inverse probability weighting in all the analyses. We 
also performed several tests that could have increased the risk of chance findings or Type I errors, however the 
association we observed was robust, given the consistency in the direction of the associations between the mod-
els, unadjusted and adjusted, and using the exposure as continuous and as categorical variable, and in line with 
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previous literature. In addition, lack of information on parental behavioural problems during pregnancy could 
have resulted in some residual confounding.
The main strengths of this study include its population-based, prospective design, and large sample size 
located in heterogeneous geographical areas. Therefore, the conclusions of the study are generalizable to the 
general population. Several methodological aspects are also considered major strengths of the study, such as 
the inclusion of important confounding variables in the statistical models, the multiple imputation of missing 
covariate values, the use of inverse probability weighting to control the potential selection bias induced by loss 
of follow-up. Finally, the inclusion of several behavioural problems domains and ages conferred a wide view of 
the role of prenatal 25(OH)D3 on neurodevelopmental alterations, not restricted to specific types of behavioural 
problems or focused on single age periods.
In conclusion, we observed that prenatal 25(OH)D3 was related to social skills at 5 years of age. On the con-
trary, we found no evidence for the association between prenatal 25(OH)D3 and several behavioural problems 
across childhood including ADHD and ASD symptoms. Further studies carried out in countries where the pop-
ulation is exposed to lower vitamin D levels are needed.
Methods
Study population. This study was embedded in the INMA Project, a population-based birth cohort based 
in different regions across Spain35. For the current study, we used data from Menorca (40°N), Valencia (39°N), 
Sabadell (41°N), Asturias (43°N), and Gipuzkoa (43°N) regions. A total of 3,126 pregnant women were recruited 
at their first routine specialized antenatal care visit (10–13 weeks of gestation) in the main public hospital or ref-
erence health centre. The recruitment took place between February 1997 and September 1998 in Menorca, and 
between November 2003 and February 2008 in the other regions. Since then, we collected data from the partic-
ipants every two years approximately. The 89.3% (2,792) of the baseline sample had 25(OH)D3 data available. A 
total of 2,107 mother-child pairs, who had 25(OH)D3 measured and at least one of the behavioural assessments 
available, were included in this study, representing the 67.4% of the initial sample (Fig. 1).
This study was approved by the Clinical Research Ethical Committees of the Asturias, Donostia (Gipuzkoa), 
and La Fe (Valencia) Hospitals, and the Medical Assistance Municipal Institute (Barcelona), all research was per-
formed in accordance with the relevant guidelines and regulations, and written informed consent was obtained 
from all participants for each phase.
25(OH)D3 assessment. A single maternal blood specimen was drawn during pregnancy (mean [SD] 13.3 
[2.8] weeks of gestation). Most blood draws (78.6%) were done during the second trimester of pregnancy, with 
20.6% during the first trimester, and 0.8% during the third trimester. We also measured child plasma concen-
trations of 25(OH)D3 in a subgroup of 808 participants (mean [SD] 4.5 [0.2] years old). Samples were processed 
immediately and stored from −70 to −80 °C until analysis. Plasma concentrations of 25(OH)D3 were quantified 
by high-performance liquid chromatography method using a BioRAD kit according to Clinical and Laboratory 
Standard Institute protocols36. Detection limit was 5 ng/ml, and interassay coefficient of variation was 4.5%. The 
assay was validated by German Programes of External Evaluation of Quality (DGKL-RFB-Referenzinstitut für 
Bionalytik), and results were satisfactory in 100% of the cases.
Neurodevelopmental outcomes assessment. ASD symptoms were measured through the Childhood 
Autism Spectrum Test (CAST)37. A psychologist administered this 37-item questionnaire to the child’s parents. 
The CAST identifies subtle manifestations of autism spectrum conditions (social impairments, communication 
impairments, and repetitive or stereotyped behaviours). The total score ranges from 0 to 31 points.
Social competence was reported by teachers using the California Preschool Social Competence Scale 
(CPSCS)38. The CPSCS consists of 30 items that result into scores for five subscales (considerateness, task orien-
tation, extraversion, verbal facility, and response to unfamiliar) and a general social competence score. The scores 
were standardized to a mean of 100 and a standard deviation of 15.
Behavioural problems were reported by parents using SDQ39 and CBCL40. The SDQ consists of 25 items with 
five for each dimension: emotional problems, conduct problems, hyperactivity/inattention problems, peer/social 
problems, and pro-social behaviour. The sum of the four problematic scores (excluding pro-social behaviour) 
Women recruited in 
pregnancy (n=3,126) 
Maternal blood extraction 
and measurement of 
25(OH)D3 during pregnancy 
(mean [SD] 13.3 [2.8] 
weeks of gestation) 
(n=2,792) 
Child neurodevelopmental 
assessment at 5, 8, 14 and 
18 years old (n=2,107) 
Regions  
Menorca (n=482) 
Valencia (n=855) 
Sabadell (n=657) 
Asturias (n=494) 
Gipuzkoa (n=638) 
Regions  
Menorca (n=261) 
Valencia (n=516) 
Sabadell (n=488) 
Asturias (n=399) 
Gipuzkoa (n=443) 
Figure 1. Flowchart of study population.
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yields a total behavioural problems score, ranging from 0 to 40. Regarding the CBCL, we used the version for 
children between 6 and 18 years old, comprised by 113 items that measure nine dimensions: anxious/depressed, 
withdrawn/depressed, somatic complaints, social problems, thought problems, attention problems, rule-breaking 
behaviour, aggressive behaviour, and other problems. The sum of all subscales’ scores yields a total behavioural 
problems score, ranging from 0 to 240.
ADHD symptoms were reported by parents using the CPRS-R (S)41. This questionnaire comprises 27 items 
that result into scores for three subscales (oppositional, cognitive problems/inattention, hyperactivity), and a 
general ADHD index, ranging from 0 to 36.
Covariates assessment. During the first trimester of pregnancy, we used questionnaires to collect maternal 
background information, such as age, country of birth (Spain, Latin America, Europe, and other country), educa-
tion level (primary or lower, secondary, and university degree), social class (managers/technicians, non-manual, 
and manual occupation)42, parity (0, 1, 2 or more), and pre-pregnancy body mass index (BMI) based on meas-
ured height at recruitment and pre-pregnancy self-reported weight (kilograms per square meter, kg/m2; under-
weight [<18.5], normal weight [18.5, <25], overweight [25, <30], and obese [≥30]). We collected information 
on active smoking and partner smoking at home during the first trimester of pregnancy.
Statistical analysis. The concentrations of 25(OH)D3 are highly dependent on the season when they are 
measured. To take into consideration the seasonal distribution of 25(OH)D3 and to reduce the influence of com-
peting exposures not related to 25(OH)D3 status (e.g. winter infection, melatonin-related exposures, etc.), we 
deseasonalized the variable. We first tested seasonality of 25(OH)D3 concentration by fitting the data to a sine 
function with a period of 12 months in a nonlinear regression cosinor model43. We subtracted the predicted con-
centrations based on month at blood collection from the actual observed value for each subject. In our analyses, 
we used the residuals derived from the sinusoidal model, centred to the overall mean, as the exposure variable. 
Maternal and child 25(OH)D3 concentrations were treated as continuous (effect per 10 ng/ml increment) and as 
categorical divided into clinically relevant categories (<20 ng/ml [deficiency, reference group], 20 to 29.9 ng/ml 
[insufficiency], and ≥30 ng/ml [sufficiency]). Although there is no absolute consensus regarding the cut-offs that 
should be used, most experts agree on these categories44.
We ran linear regression models to examine the association between maternal 25(OH)D3 concentration in 
pregnancy and ASD symptoms, social competence, and total behavioural problems measured with the SDQ, 
as continuous scores. Negative binomial regression models were used for total behavioural problems measured 
with the CBCL and ADHD symptoms as continuous scores. Regression models were performed unadjusted, 
minimally adjusted (for region), and fully adjusted (for maternal age, maternal education level, maternal occu-
pation, maternal country of birth, maternal smoking during pregnancy, and partner smoking at home during 
pregnancy). The confounding variables were defined based on scientific literature and on availability of data 
within the INMA Project.
We performed multiple imputations of missing values using chained equations to impute missing potential 
confounding variables among all participants with available data on the exposure and the outcomes. We gener-
ated and separately analysed twenty-five completed data sets and we combined the results using the standard 
Rubin’s rules45, assuming missing at random data.
Children included in the analysis (n = 2,107) were more likely to have parents from a higher socioeconomic 
position compared to children that were not included due to missing data in either the exposure or one of the 
outcomes (n = 1,019). We therefore applied inverse probability weighting (IPW) to correct for selection bias that 
potentially arises when only population with available exposure and outcome data is included as compared to the 
full initial cohort recruited at pregnancy46.
As sensitivity analyses, we repeated all the models using child 25(OH)D3 concentration as exposure varia-
ble, instead of maternal concentrations during pregnancy, in order to assess the associations between postnatal 
25(OH)D3 and the outcomes.
We performed all the statistical analyses using Stata 12.0 (Stata Corporation, College Station, Texas).
Data Availability
The datasets generated during and/or analysed during the current study are not publicly available but are available 
from the corresponding author on reasonable request.
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